Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LX201 dose-ranging study for prevention of corneal graft rejection after penetrating keratoplasty
2007-000295-16Phase 2Completed
- Sponsor
- Lux Biosciences, Inc.
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of LX201 in keratoplasty rejection (CGR) (3 arms), sponsored by Lux Biosciences, Inc. Primary endpoint: Primary efficacy endpoint. Started Apr 2007; status: completed.
02
Drugs
LX201
03
Conditions
keratoplasty rejection (CGR)
Beyond the preview
Go deeper on 2007-000295-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000295-16.